Radiomics Analysis of 177Lu-PSMA I&T Radioligand Therapy Dosimetry in a Castration Resistant Metastatic Prostate Cancer Patient

177Lu-DOTAGA-(l-y)fk(Sub-KuE) (177Lu-PSMA I&T) is currently used for

radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC)

in several centers in Europe. It was launched in Tallinn, Estonia, in December 2018. As

an additional project, a model of dosimetric analysis was created, utilizing voxel-based

dosimetry and intra-lesion radiomics to assess their practicality in routine dosimetry

[1]. This was a successful project, and the work is summarized in this chapter.

Keywords: 177Lu isotope, Dosimetry, Positron emission tomography, Prostate cancer, PSMA, Quantitative SPECT, Radiomics, Radionuclide therapy, Voxelbased dosimetry.

Cite as

Current Dentistry

Current Psychopharmacology

Recent Advances in Anti-Infective Drug Discovery

Anti-Infective Agents

Adolescent Psychiatry

Current Alzheimer Research

Current Aging Science

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Current Diabetes Reviews

Current HIV Research

Andrology: Current and Future Developments

Male Infertility: An Integrative Manual of Western and Chinese Medicine

Awake Thoracic Surgery

The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy

Frontiers in Anti-infective Agents

The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo